Trial Profile
Phase IV Study Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary) ; Raloxifene (Primary) ; Teriparatide
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Mar 2012 Results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
- 23 Feb 2012 New source identified and integrated (ClinicalTrials.gov NCT01535027).